☰

Todd A. Triplett - Publications

Affiliations: 
University of Texas at Austin, Austin, Texas, U.S.A. 
Tree Info Similar researchers PubMed Report error

17/26 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Holay N, Somma A, Duchow M, Soleimani M, Capasso A, Kottapalli S, Rios J, Giri U, Diamond J, Schreiber A, Piscopio AD, Van Den Berg C, Eckhardt SG, Triplett TA. Elucidating the direct effects of the novel HDAC inhibitor bocodepsin (OKI-179) on T cells to rationally design regimens for combining with immunotherapy. Frontiers in Immunology. 14: 1260545. PMID 37744352 DOI: 10.3389/fimmu.2023.1260545  0.532
2020 Lyu A, Triplett TA, Nam SH, Hu Z, Arasappan D, Godfrey WH, Ames RY, Sarang A, Selden HJ, Lee CH, Georgiou G, Horton TM, Ehrlich LIR. Tumor-associated myeloid cells provide critical support for T-ALL. Blood. PMID 32845007 DOI: 10.1182/Blood.2020007145  0.656
2020 Bloom MJ, Jarrett AM, Triplett TA, Syed AK, Davis T, Yankeelov TE, Sorace AG. Anti-HER2 induced myeloid cell alterations correspond with increasing vascular maturation in a murine model of HER2+ breast cancer. Bmc Cancer. 20: 359. PMID 32345237 DOI: 10.1186/S12885-020-06868-4  0.302
2020 Warden AS, Triplett TA, Lyu A, Grantham EK, Azzam MM, DaCosta A, Mason S, Blednov YA, Ehrlich LIR, Mayfield RD, Harris RA. Microglia depletion and alcohol: Transcriptome and behavioral profiles. Addiction Biology. e12889. PMID 32176824 DOI: 10.1111/Adb.12889  0.67
2019 Bloom M, Jarrett A, Triplett T, Syed A, Yankeelov T, Sorace A. Abstract P4-06-17: Investigating trastuzumab-induced myeloid cell alterations for improving combination therapy in HER2+ breast cancer Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-P4-06-17  0.425
2019 Bloom MJ, Jarrett AM, Triplett TA, Syed AK, Yankeelov TE, Sorace AG. Abstract 187: Trastuzumab induced myeloid cell alterations identifies mechanistic properties of vascular normalization Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-187  0.329
2019 Miljanic M, Holay N, Capasso A, Triplett T, Soleimani M, Giri U, Berg CVD, Eckhardt G. Abstract 4753: Attenuating colorectal cancer cell growth and enhancing immunogenicity through rational combination of MEK and HDAC inhibition Cancer Research. 79: 4753-4753. DOI: 10.1158/1538-7445.Am2019-4753  0.48
2018 Triplett TA, Garrison KC, Marshall N, Donkor M, Blazeck J, Lamb C, Qerqez A, Dekker JD, Tanno Y, Lu WC, Karamitros CS, Ford K, Tan B, Zhang XM, McGovern K, et al. Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme. Nature Biotechnology. PMID 30010674 DOI: 10.1038/Nbt.4180  0.477
2017 Triplett TA, Triplett K, Stone E, Zhang M, Manfredi M, Lamb C, Tanno Y, Ehrlich L, Georgiou G. Abstract 5571: Immune-checkpoint inhibition via enzyme-mediated degradation of kynurenine Cancer Research. 77: 5571-5571. DOI: 10.1158/1538-7445.Am2017-5571  0.767
2017 Zhang M, Stone E, Triplett TA, Triplett K, Lamb C, Karamitros CS, Blazek J, Georgiou G, Manfredi MG. Abstract 5570: A novel approach to targeting the IDO/TDO pathway through degradation of the immunosuppressive metabolite kynurenine Cancer Research. 77: 5570-5570. DOI: 10.1158/1538-7445.Am2017-5570  0.501
2017 Triplett TA, Lyu A, Godfrey W, Ehrlich LIE. Abstract 2965: Myeloid depletion reverses established T-ALL growthin vivo Cancer Research. 77: 2965-2965. DOI: 10.1158/1538-7445.Am2017-2965  0.746
2016 Triplett TA, Cardenas KT, Lancaster JN, Hu Z, Selden HJ, Jasso GJ, Balasubramanyam S, Chan K, Li L, Chen X, Marcogliese AN, Davé UP, Love PE, Ehrlich LI. Endogenous dendritic cells from the tumor microenvironment support T-ALL growth via IGF1R activation. Proceedings of the National Academy of Sciences of the United States of America. PMID 26862168 DOI: 10.1073/Pnas.1520245113  0.663
2015 Triplett TA, Tucker CG, Triplett KC, Alderman Z, Sun L, Ling LE, Akporiaye ET, Weinberg AD. STAT3 Signaling Is Required for Optimal Regression of Large Established Tumors in Mice Treated with Anti-OX40 and TGFβ Receptor Blockade. Cancer Immunology Research. 3: 526-35. PMID 25627655 DOI: 10.1158/2326-6066.CIR-14-0187  0.573
2015 Triplett TA, Cardenas KT, Jones JN, Selden HJ, Jasso GJ, Balasubramanyam S, Hu Z, LiQi L, Love PE, Ehrlich LI. Abstract A02: Altered myeloid cells in the tumor microenvironment promote growth of T cell acute lymphoblastic leukemia. Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Hemmal14-A02  0.819
2015 Stone E, Marshall N, Donkor M, Triplett K, Blazek J, Triplett T, Ehrlich L, Georgiou G. Abstract LB-226: Depletion of kynurenine using an engineered therapeutic enzyme potently inhibits cancer immune checkpoints both as a monotherapy and in combination with anti-PD-1 Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Lb-226  0.747
2013 Akporiaye ET, Tucker C, Triplett T, Garrison K, Sun L, Ling L, Weinberg A. STAT3 signaling is required for anti-OX40/TGF-β receptor blockade-mediated regression of large established tumors Journal For Immunotherapy of Cancer. 1. DOI: 10.1186/2051-1426-1-S1-P68  0.63
2012 Triplett TA, Curti BD, Bonafede PR, Miller WL, Walker EB, Weinberg AD. Defining a functionally distinct subset of human memory CD4+ T cells that are CD25POS and FOXP3NEG. European Journal of Immunology. 42: 1893-905. PMID 22585674 DOI: 10.1002/Eji.201242444  0.354
Low-probability matches (unlikely to be authored by this person)
2023 Anderson KG, Braun DA, Buqué A, Gitto SB, Guerriero JL, Horton B, Keenan BP, Kim TS, Overacre-Delgoffe A, Ruella M, Triplett TA, Veeranki O, Verma V, Zhang F. Leveraging immune resistance archetypes in solid cancer to inform next-generation anticancer therapies. Journal For Immunotherapy of Cancer. 11. PMID 37399356 DOI: 10.1136/jitc-2022-006533  0.298
2022 Soleimani M, Somma A, Kaoud TS, Goyal R, Bustamante J, Wylie DC, Holay N, Looney AP, Giri U, Triplett T, Dalby KN, Kowalski J, Eckhardt SG, Van Den Berg C. Covalent JNK inhibitor, JNK-IN-8, suppresses tumor growth in triple-negative breast cancer by activating TFEB and TFE3 mediated lysosome biogenesis and autophagy. Molecular Cancer Therapeutics. PMID 35977156 DOI: 10.1158/1535-7163.MCT-21-1044  0.271
2019 Holay N, Giri U, Miljanic M, Soleimani M, Shaikh O, Capasso A, Berg CLVD, Eckhardt G, Triplett T. Abstract 1088: Unleashing the potential of HDACi to augment immunotherapy for the treatment of colorectal cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-1088  0.246
2020 Lee MW, Miljanic M, Triplett T, Ramirez C, Aung KL, Eckhardt SG, Capasso A. Current methods in translational cancer research. Cancer Metastasis Reviews. PMID 32929562 DOI: 10.1007/S10555-020-09931-5  0.24
2023 Schreiber AR, Kagihara JA, Corr BR, Davis SL, Lieu C, Kim SS, Jimeno A, Camidge DR, Williams J, Heim AM, Martin A, DeMattei JA, Holay N, Triplett TA, Eckhardt SG, et al. First-in-Human Dose-Escalation Study of the Novel Oral Depsipeptide Class I-Targeting HDAC Inhibitor Bocodepsin (OKI-179) in Patients with Advanced Solid Tumors. Cancers. 16. PMID 38201519 DOI: 10.3390/cancers16010091  0.163
2020 Miljanic M, Capasso A, Triplett TA, Eckhardt SG, Aung KL. Immune Checkpoint Blockade in Gastrointestinal Cancers: The Current Status and Emerging Paradigms. Journal of Immunotherapy and Precision Oncology. 3: 3-15. PMID 35756177 DOI: 10.4103/JIPO.JIPO_1_20  0.156
2012 Redmond WL, Triplett T, Floyd K, Weinberg AD. Dual anti-OX40/IL-2 therapy augments tumor immunotherapy via IL-2R-mediated regulation of OX40 expression. Plos One. 7: e34467. PMID 22496812 DOI: 10.1371/journal.pone.0034467  0.152
2022 Bazzi SA, Maguire C, Holay N, Geltman J, Hurley K, DiPasquale C, Abigania M, Olson E, Ehrlich LIR, Triplett TA, Melamed E. Longitudinal COVID-19 immune trajectories in patients with neurological autoimmunity on anti-CD20 therapy. Multiple Sclerosis and Related Disorders. 68: 104195. PMID 36223705 DOI: 10.1016/j.msard.2022.104195  0.149
2023 Siles N, Schuler M, Maguire C, Amengor D, Nguyen A, Wilen R, Rogers J, Bazzi S, Caslin B, DiPasquale C, Abigania M, Olson E, Creaturo J, Hurley K, Triplett TA, et al. SARS-CoV-2 Humoral Immune Responses in Convalescent Individuals Over 12 Months Reveal Severity-Dependent Antibody Dynamics. Medrxiv : the Preprint Server For Health Sciences. PMID 38106077 DOI: 10.1101/2023.12.05.23299462  0.068
Hide low-probability matches.